Soleno only has one indication, their first Phase 3 trial (C601) did not meet primary endpoint, then did another one (C602).
Soleno market cap was US$2.25B before the FDA approval, now its share price rises 32.73% after-market, its market cap is US$3B.
NEU's market cap is US$0.96B.
- With US$220m cash,
- Approved DAYBUE, partnered with Acadia, receiving annual royalties and milestone payments,
- Phase 3 for PMS anticipated to start mid 2025, PMS addressable market size is 2 to 3 times of DAYBUE;
- Two successful concluded Phase 2 trials;
- New indications.
Maybe JP should consider to be dual listing in Nasdaq?
Ann: Prader-Willi syndrome IND for NNZ-2591 approved by FDA, page-26
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$13.10 |
Change
-0.800(5.76%) |
Mkt cap ! $1.629B | |||
| Open | High | Low | Value | Volume |
| $13.95 | $13.96 | $12.88 | $9.534M | 725.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 266 | $13.10 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.15 | 1619 | 2 |
View Market Depth
| Last trade - 16.10pm 13/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |